Just a quick follow up on my post from yesterday.

In terms of trial timing just the phase 1b/2 TNBC trial with Pfizer and zen3694 is slated to last well into 2020.

I did notice a phrase in the press reslease that I had not noted before. Don stated - 

“We are pleased with the continued clinical advancements with ZEN-3694 in diseases with significant unmet need,” said Donald McCaffrey, Chief Executive Officer of Zenith. “We look forward to the first dosing of patients in our collaboration trial with Pfizer, as well as future key clinical milestones. 

I had not noticed the part about future milestones. Do we know anything about the TNBC trial contract and if it contains milestones? If so, it could bode well if there are some sort of performance terms that impact the future value of Zenith.

Anyway, I'm grasping at straws because I would like to see some liquidity far sooner than than the time frame I expressed yesterday.

GLTA

Toinv